California AB1990 establishes new regulations for compounded medications used for obesity and weight management, requiring that bulk drug substances come from FDA-registered manufacturers inspected within the last two years, possess valid certificates of analysis, and are not subject to FDA import alerts. The bill mandates written verification from manufacturers and wholesalers, requires two years of record-keeping, allows California State Board of Pharmacy inspections, and imposes penalties of up to $1,000 per dose and potential license revocation for violations. Advertisements for these compounded medications must include truthful disclosures about potential side effects and clearly state that the product is compounded, not FDA-approved, and has not been evaluated for safety or efficacy.
Why It Matters to MAHA
MAHA opposes this bill because it creates unnecessary regulatory barriers that restrict patient access to compounded medication options. While consumer protection through transparency is important, this legislation imposes burdensome compliance requirements and steep penalties that may discourage pharmacies from offering compounded weight management medications, ultimately limiting patient choice. The bill prioritizes regulatory control over the ability of patients and their doctors to access innovative compounded treatments that may not be available through FDA-approved channels. Rather than trusting the patient-physician relationship and market competition to drive quality, AB1990 uses heavy-handed penalties and restrictions that disproportionately burden compounding pharmacies and reduce treatment options.